Headquartered in Bangalore and Delaware, cell therapy startup Eyestem secured $6.4 million in its Series A funding round at a post-money valuation of $46.4 million. The funding was led by three Indian pharma majors- Biological E. Limited, Alkem, NATCO and Anurag and Karan Bagaria, promoters of Kemwell Biopharma. Existing investors...